Global Huntington's Disease Treatment Market: Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2028

 

Huntington's disease, also known as Huntington's chorea, is an inherited, autosomal dominant, rare condition that gradually impairs a person's physical and mental abilities. It is characterized by progressive degeneration of brain nerve cells. Typically, Huntington's disease symptoms appear between the ages of 30 and 50, and they progressively worsen over the course of the subsequent 10 to 25 years. Typically, movement disorders, cognitive disorders, or psychiatric disorders are linked to Huntington's disease. In the end, the person is more prone to developing pneumonia, developing heart failure, or dying from other complications. Neurological testing, neuropsychological testing, psychiatric assessment, genetic testing, and brain imaging and functioning are used to make a preliminary diagnosis of Huntington's disease.

Huntington's Disease Treatment Market can be treated symptomatically with medications like tetrabenazine, antidepressants, antipsychotics, or mood stabilizers. Additionally, the patient's life can be improved by psychotherapy, speech therapy, physical therapy, occupational therapy, or lifestyle and home remedies.

However, some symptoms of psychiatric and movement disorders can be reduced by medication. Additionally, for a limited period of time, numerous interventions can aid a person in adjusting to changes in their abilities.

Huntington's Disease Treatment Market, also referred to as Huntington's chorea is a rare hereditary condition that slowly destroys brain nerve cells, impairing a person's physical and mental abilities. The first signs of Huntington's disease typically appear between the ages of thirty and fifty, and they get worse ten to twenty-five years after the disease first manifests.

Huntington's disease is frequently associated with issues with mobility, cognition, or psychological well-being. The individual eventually develops a susceptibility to the flu, cardiac arrest, or other conditions that result in death. Huntington's Disease Treatment Market is initially diagnosed using a neurological evaluation, cognitive testing, psychiatric evaluation, antibody test, and brain scans and functionality.

Key Players

The main players in the market for treating Huntington's disease are Valeant Pharmaceuticals International Inc., Alnylam Pharmaceuticals Inc., Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Prana Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer